tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
Context Therapeutics (CNTX)
NASDAQ:CNTX
CNTX
Context Therapeutics
Stock Analysis
Analyst Forecasts
Technical Analysis
Chart
Earnings
Dividends
Ownership
Financials
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Holding CNTX?
Track your performance easily
Link Broker

Context Therapeutics (CNTX) Stock News & Sentiment

93 Followers
Context Therapeutics Secures Funding for Cancer Therapy Pipeline
Premium
Company Announcements
Context Therapeutics Secures Funding for Cancer Therapy Pipeline
25d ago
8K
CNTX
Context Therapeutics: Strategic Developments and Financial Outlook
Premium
Company Announcements
Context Therapeutics: Strategic Developments and Financial Outlook
1M ago
CNTX
Context Therapeutics Acquires Rights to Innovate Cancer Antibodies
Premium
Company Announcements
Context Therapeutics Acquires Rights to Innovate Cancer Antibodies
3M ago
8K
CNTX
Context Therapeutics Bolsters Board with Industry Veterans
Premium
Company Announcements
Context Therapeutics Bolsters Board with Industry Veterans
4M ago
8K
CNTX
Context Therapeutics Acquires CT-95 for Cancer Trial Launch
Premium
Company Announcements
Context Therapeutics Acquires CT-95 for Cancer Trial Launch
6M ago
8K
CNTX
Context Therapeutics Secures Funding, Advances Clinical Trials
Premium
Company Announcements
Context Therapeutics Secures Funding, Advances Clinical Trials
8M ago
8K
CNTX
Context Therapeutics Advances Cancer Trial with FDA Submission
Premium
Company Announcements
Context Therapeutics Advances Cancer Trial with FDA Submission
9M ago
8K
CNTX
More CNTX News >

CNTX News on the Web

Context Therapeutics Secures Funding for Cancer Therapy Pipeline
TipRanks News
Neutral
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s 39th Annual Meeting
Yahoo Finance
Neutral
Buy Rating Affirmed for Context Therapeutics Amid Strategic Licensing and Promising TCE Portfolio Expansion
TipRanks News
Bullish
Buy Rating Issued for Context Therapeutics on CT-202’s Innovative TCE Approach and Market Potential
TipRanks News
Bullish
Context Therapeutics Acquires Rights to Innovate Cancer Antibodies
TipRanks News
Neutral
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Yahoo Finance
Neutral
We Think Context Therapeutics Can Afford To Drive Business Growth
Yahoo Finance
Neutral
Piper Sandler Sticks to Its Buy Rating for Context Therapeutics (CNTX)
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CNTX’s Media Buzz Sentiment?
Currently, no data Available
What is CNTX’s weekly average amount of articles?
Currently, no data Available
What is CNTX’s News Sentiment?
Currently, no data Available
Healthcare Stocks that are Trending in the News
ENSGThe Ensign Group
OPRXOptimizeRx
DOCSDoximity
PVLAPalvella Therapeutics
PBYIPuma Biotechnology
Showing the stocks with the most bullish news sentiment over the past week

Become an Expert with TipRanks Premium

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis
Subscribe NowSee Plans & Pricing